Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation

• Status: Unknown status
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

We hypothesized that in patients with low CHADS-VASc score (2 or < 2), there is no difference in thromboembolic or bleeding events between patients with short term warfarin therapy (2 weeks after catheter ablation) and conventional therapy (3 weeks before and 8 weeks after procedure).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Korea University Anam Hospital
• Treatments: Warfarin

Criteria

Inclusion Criteria:

• Patients with paroxysmal atrial fibrillation who underwent radiofrequency catheter ablation

• Patients with CHADS-VASc score 2 or less than 2

Exclusion Criteria:

• Patients who do not consent to the study

• Permanent or persistent atrial fibrillation

• Patients who have underwent prior catheter ablation for atrial fibrillation

• CHADS-VASc score more than 2

• History of stroke

• LVEF <40%

• Significant liver or kidney dysfunction

• History of major bleeding during warfarin therapy